CN1221268C - Magnesium-calcium ion composite preparation and production precess thereof - Google Patents
Magnesium-calcium ion composite preparation and production precess thereof Download PDFInfo
- Publication number
- CN1221268C CN1221268C CN 02130855 CN02130855A CN1221268C CN 1221268 C CN1221268 C CN 1221268C CN 02130855 CN02130855 CN 02130855 CN 02130855 A CN02130855 A CN 02130855A CN 1221268 C CN1221268 C CN 1221268C
- Authority
- CN
- China
- Prior art keywords
- magnesium
- calcium
- calcium ion
- acetate
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229910001424 calcium ion Inorganic materials 0.000 title claims abstract description 22
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000002131 composite material Substances 0.000 title abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000011777 magnesium Substances 0.000 claims abstract description 26
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 25
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 22
- 239000000243 solution Substances 0.000 claims abstract description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 13
- 239000008101 lactose Substances 0.000 claims abstract description 13
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000001639 calcium acetate Substances 0.000 claims abstract description 12
- 235000011092 calcium acetate Nutrition 0.000 claims abstract description 12
- 229960005147 calcium acetate Drugs 0.000 claims abstract description 12
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000011654 magnesium acetate Substances 0.000 claims abstract description 12
- 235000011285 magnesium acetate Nutrition 0.000 claims abstract description 12
- 229940069446 magnesium acetate Drugs 0.000 claims abstract description 12
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 11
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 10
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 10
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011259 mixed solution Substances 0.000 claims abstract description 5
- 229960000583 acetic acid Drugs 0.000 claims description 14
- 239000012362 glacial acetic acid Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 229940013618 stevioside Drugs 0.000 claims description 7
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 7
- 235000019202 steviosides Nutrition 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 24
- 239000011575 calcium Substances 0.000 abstract description 24
- 229910052791 calcium Inorganic materials 0.000 abstract description 24
- 229910001425 magnesium ion Inorganic materials 0.000 abstract description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 208000001132 Osteoporosis Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 208000015606 cardiovascular system disease Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 229940091250 magnesium supplement Drugs 0.000 description 25
- 229960005069 calcium Drugs 0.000 description 23
- 229910052500 inorganic mineral Inorganic materials 0.000 description 14
- 235000010755 mineral Nutrition 0.000 description 14
- 239000011707 mineral Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000011001 calcium citrates Nutrition 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010090279 galactose permease Proteins 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960002203 tilactase Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a magnesium-calcium ion composite preparation and a producing technology thereof, which is characterized in that acetic acid glacial is used by the present invention so as to chemically react with magnesium oxide and calcium carbonate respectively, magnesium acetate solution and calcium acetate solution are generated, and a proper amount of lactose and other auxiliary raw materials are added after the magnesium acetate solution and the calcium acetate solution are mixed so that the magnesium-calcium ion composite preparation is produced. Each 10 milliliters of mixed solution contains 70 milligrams of magnesium ions and 200 milligrams of calcium ions, and the content ratio of the magnesium ions to the calcium ions is 1: 2 to 4.The products are mainly used for specific nutrient replenishers, and are applicable to people who lack magnesium and calcium and are mainly patients with cardiovascular system disease and patients with osteoporosis. The present invention can be used for the prevention and the auxiliary treatment of diseases of the kinds.
Description
Technical field
Dietary supplement-magnesium calcium ion compound formulation and the production technology thereof that the present invention relates to a kind of magnesium calcium macroelement of additional needed by human body and develop.
Background technology
Mineral is relevant with bodily tissue, and is also relevant with the function of various systems, as the formation of blood and skeleton, and neural function, the adjusting of muscle.Mineral can be used as the metabolism that coenzyme participates in material, the production of energy, the utilization of vitamin and other nutrient.Human body must be kept normal chemical equilibrium, and this balance will rely on the ratio of mineral in the body.If a kind of mineral is out of proportion, produce chain reaction just can influence all mineral, so that the chemical reaction disequilibrium, and cause disease.At present, in developed country mineral and vitamin are lumped together and to make tablet, as health food or meals tonic.General mineral is to form with the form of chelating with protein, mineral is absorbed easily and transports in blood.Take mineral in the time of on the feed, the digestion process mineral forms chelate under one's belt and is absorbed.The dose of mineral can not be excessive, and when its major reason was absorption, they were vied each other, if a certain mineral is too much, just can squeeze out other mineral other mineral are lacked.Calcium is one of more element of human body appetite, content in human body is only second to hydrogen, oxygen, carbon, nitrogen and occupy the 5th, and calcium is about 1300g in the total amount of human body, the 1.5-0.75% of about percentage of liveweight, wherein 99% calcium is present in skeleton, and skeleton is the mainstay of human body.Though the calcium outside the skeleton only accounts for 1%, it plays an important role in vivo, and calcium is present in the outer liquid of thin bag, soft tissue, and be one of composition of cell membrane.Calcium participates in coagulation process, to the contraction of muscle, comprises the normal effect and nervimuscular stress the playing an important role of cardiac muscle.If ionized calcium obviously descends in blood plasma, then nervimuscular irritability will increase greatly, so that tetany.On the contrary, if calcium ion is too high in blood, then can cause the depletion of heart and breathing.Magnesium is all relevant to the performance of the many functions of human body, and magnesium is being brought into play extremely delicate effect aspect the balance of keeping the health holistic health.The effect of magnesium maximum is that the calcium of circulation in the pair cell is regulated.This just delicate coordination is determining the frequency of human body cell flame.Magnesium and calcium have been formed special fellowship in the process of production adenosine triphosphate (ATP).The ATP enzyme is that we are engaged in any active power producer, and it is deposited with living cells inside, and magnesium is being guarded these cell gates, and calcium could produce enough ATP inside only entering.Magnesium all plays activation to 300 plurality of enzymes in the human body, and all protein building-up process of human body all need magnesium to participate in.The hydrolysis of nucleic acid absorbs and utilizes process that the participation of magnesium must be arranged.Magnesium not only influences the glucose conversion in the blood, also influences fat and energy metabolism.Now calcium carbonate and magnesium oxide directly are pressed into tablet respectively, the perhaps synthetic tablet that is pressed into is very general abroad.Because calcium magnesium is Yanggao County's of bivalence, need to rely on the gastric acid dissolving after taking, 100 milligrams calcium carbonate dissolves fully needs 230 milliliters gastric acid, and as if every day is overweight less than 1000 milliliters gastric acid burden concerning the old people.If calcium, magnesium are taken respectively, also exist the not wield problem of dose ratio, the competition each other of calcium, magnesium ion absorbs, and dried scratching influenced absorbance mutually.
Summary of the invention
Purpose of the present invention is exactly to develop a kind of best concentration ratio that absorbs by the human intestines and stomach, with magnesium calcium ion compound formulation and the production technology thereof of liquid as calcium, magnesium ion carrier.
Magnesium calcium ion compound formulation production technology scheme of the present invention is as follows:
Need use the burdening calculation materials by the magnesium calcium compound formulation of producing 1000 milliliters, need:
Glacial acetic acid 124-138 milliliter
Calcium carbonate 51-57 gram
Magnesium oxide 11-12 gram
Lactose 9.5-10.5 gram
Stevioside 6-7 gram
All the other are deionized water
Production technology:
Carry out chemical reaction with magnesium oxide and calcium carbonate respectively with acetic acid, generate magnesium acetate solution and calcium acetate solution, calcium acetate solution and magnesium acetate solution are mixed, form mixed liquor.In solution, add an amount of lactose and other auxiliary material.Make solution reach the concentration of regulation: in per 10 milliliters of mixed liquors, to contain 70 milligrams of magnesium ions, 200 milligrams of calcium ions.
The effect that adds glacial acetic acid in the production is to form calcium acetate solution with the acetate dissolution calcium carbonate, acetic acid and magnesium oxide reaction generate magnesium acetate solution, in magnesium acetate and calcium acetate solution, magnesium, calcium are the divalent ionic state and exist, and that is to say that the state that is after gastric acid dissolves exists.Old people's gastric acid secretion and pepsin are synthetic to be reduced, can not fully dissolve absorption to magnesium, calcium, and this product element all is the liquid ions state, is easily directly absorbed by intestinal, acetate is not only to the effect of human body that to be beneficial to several amino acids synthetic, can also strengthen microcirculation by blood vessel dilating.This product adds a certain amount of lactose, promotes the absorption of calcium, magnesium with lactose.Lactose only exists in milk, is that parent is supplied with the most important nutrient substance of baby.After lactose enters human body, be decomposed into galactose rapidly, form tilactase, galactose permease etc. not only promote the absorption of magnesium, can also strengthen the activation of magnesium to enzyme.The concentration ratio of this product magnesium and calcium ion more meets Chinese diet and physiological feature.Medical research finds that magnesium, calcium ion concentration ratio are in the intestinal at 1: 2 o'clock, and absorbance is higher.The magnesium calcium preparation of external import, the magnesium calcium content is than designing by 1: 2 usually.But, Chinese's calcium in diet content is on the low side, majority take the calcium magnesium preparation of import, calcium, magnesium density ratio can not reach 1: 2 state, this product has increased the content of calcium, make magnesium, calcium concentration ratio reach 1: 2-4, after majority took, the magnesium in the intestinal, calcium concentration were than more near 1: 2 state.This product has solved senior health and fitness's principal contradiction, cardiovascular and cerebrovascular disease, diabetes and osteoporosis.Per 10 milliliters this product oral liquid, 200 milligrams of calcium ions, be equivalent to 500 milligrams of calcium carbonate, really (sugar) sour calcium is 1532 milligrams, 2237 milligrams of calcium gluconate, 2853 milligrams of calcium citrates, be the specific nutrient supplement of magnesium supplement and calcium, being applicable to magnesium calcium deficiency crowd, mainly is cardiovascular system diseases and osteoporosis patient, can be used for the prevention and the auxiliary treatment of this type of disease.
Description of drawings
Process chart of the present invention
The specific embodiment
Embodiment 1
Get 64 milliliters of glacial acetic acid, it is diluted to the glacial acetic acid of 10% concentration, drop into then in the reactor, be warming up to 50 ℃, get 54 gram Paris whites, slowly add and stirs and continue to be warming up to 75 ℃, constant temperature continued to react in 35 minutes.Other gets 67 milliliters glacial acetic acid, and it is diluted to the glacial acetic acid of 10% concentration, drops in the reactor, is warming up to 50 ℃, gets 11.5 gram magnesium oxide, slowly adds reactor and stirring, continues to be warming up to 70 ℃, and constant temperature continued reaction in 25 minutes.Above-mentioned two kinds of reaction product calcium acetate solutions and magnesium acetate solution are put into same container mix, in mixed solution, add the stevioside of 6.5 grams, 10 gram lactose.To prepare liquid and be warming up to 90 ℃, and constant temperature to 45 minute, make it fully finish reaction.Naturally cool to room temperature.Solution is filtered with filter.Deionized water is added through filtering preparation liquid, to 1000 milliliters of amount of preparation.Be sub-packed in the vial 100 ℃ of sterilizations of flowing steam 30 minutes then.The product that obtains, magnesium, calcium ion concentration ratio are 1: 2.86.
Embodiment 2
Get 61 milliliters and 63 milliliters of glacial acetic acid respectively, after it is diluted to the glacial acetic acid solution of 10% concentration, get calcium carbonate 51 grams, magnesium oxide 11 grams, with the technology identical with embodiment 1, make the mixed solution of calcium acetate and magnesium acetate, add the stevioside of 6 grams and the lactose of 9.5 grams, use the technology identical to obtain product of the present invention then with embodiment 1.The product magnesium that obtains is 1: 2.4 with the calcium ion concentration ratio.
Embodiment 3
Get 67 milliliters and 71 milliliters of glacial acetic acid respectively, it is diluted to the glacial acetic acid solution of 10% concentration, get calcium carbonate 57 grams, magnesium oxide 12 grams, with the technology identical with embodiment 1, make the mixed solution of calcium acetate and magnesium acetate, add the stevioside of 7 grams and the lactose of 10.5 grams, use the technology identical to obtain product of the present invention then with embodiment 1.The product magnesium that obtains is 1: 4 with the calcium ion concentration ratio.
Claims (2)
1, a kind of production technology of magnesium calcium ion compound formulation, it is characterized in that: glacial acetic acid is diluted to 10% concentration, is warming up to 50 ℃ and carries out chemical reaction with magnesium oxide and calcium carbonate respectively, generate magnesium acetate and calcium acetate solution, after reaction temperature rises to 70-75 ℃, continue reaction 25-35 minute; With magnesium acetate and calcium acetate solution mixing formation mixed liquor, in solution, add an amount of lactose and stevioside, mixed liquor to be heated to 90 ℃, constant temperature 45 minutes is cooled to room temperature; Filter mixed liquor; Add deionized water to formula ratio; Be sub-packed in the vial 100 ℃ of flowing steams, sterilization in 30 minutes; Its prescription is as follows: be as the criterion to produce 1000 milliliters of magnesium calcium ion compound formulations
Glacial acetic acid 124-138 milliliter
Calcium carbonate 51-57 gram
Magnesium oxide 11-12 gram
Lactose 9.5-10.5 gram
Stevioside 6-7 gram
All the other are deionized water.
2, a kind of magnesium calcium ion compound formulation of producing with claim 1 magnesium calcium ion compound formulation production technology, it is characterized in that: it is the mixed solution of magnesium acetate, calcium acetate, lactose and stevioside, its magnesium, calcium ion concentration ratio are 1: 2-4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02130855 CN1221268C (en) | 2002-10-11 | 2002-10-11 | Magnesium-calcium ion composite preparation and production precess thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02130855 CN1221268C (en) | 2002-10-11 | 2002-10-11 | Magnesium-calcium ion composite preparation and production precess thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1488359A CN1488359A (en) | 2004-04-14 |
| CN1221268C true CN1221268C (en) | 2005-10-05 |
Family
ID=34144651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02130855 Expired - Fee Related CN1221268C (en) | 2002-10-11 | 2002-10-11 | Magnesium-calcium ion composite preparation and production precess thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1221268C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1732811B (en) * | 2005-08-10 | 2010-12-22 | 刘志仁 | Biochemical fresh-keeping nutritious liquid |
| CN101925357B (en) | 2008-01-28 | 2012-12-12 | 珍明珠集团有限公司 | Composition containing calcium, magnesium, zinc and vitamin D3 capable of preventing and improving osteoporosis |
| CN105078950A (en) * | 2015-08-03 | 2015-11-25 | 兰为民 | Composite preparation containing zinc, magnesium and calcium ions and preparing method of composite preparation |
| CN105125579A (en) * | 2015-09-10 | 2015-12-09 | 重庆布尔动物药业有限公司 | Calcium, magnesium and vitamin injection |
| JP6806312B2 (en) * | 2016-05-27 | 2021-01-06 | エルジー・ケム・リミテッド | Organic light emitting element |
| CN106380388A (en) * | 2016-08-24 | 2017-02-08 | 华仁药业股份有限公司 | A method of preparing medicinal magnesium acetate tetrahydrate |
-
2002
- 2002-10-11 CN CN 02130855 patent/CN1221268C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1488359A (en) | 2004-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109007800A (en) | A kind of specific full nutritional formulas and preparation method thereof for diabetic | |
| Riesenfeld et al. | Glucose homeostasis in the chicken | |
| CN1221268C (en) | Magnesium-calcium ion composite preparation and production precess thereof | |
| JP2002034592A (en) | Method for producing protein-zinc readily absorbable in body | |
| CN107373487A (en) | A kind of ferrous bisglycinate chelate electuary | |
| CN101513225A (en) | Composite calcium preparation added with organic germanium and preparation method and use thereof | |
| CN107417556A (en) | L aspartase calciums and preparation method thereof | |
| CN113616667A (en) | Nucleotide composition for adjuvant therapy of diabetes mellitus and preparation method and application thereof | |
| AU2016311131B2 (en) | Mineral compositions for stimulating the carbohydrate metabolism | |
| CN103735556A (en) | Multivitamin mineral composite effervescent tablet and preparation method thereof | |
| Elia | Principles of Clinical Nutrition: Contrasting the practice of nutrition in health and disease | |
| CN107441117A (en) | A kind of Muhivitamin Formula With Minerals calcium preparation and preparation method thereof | |
| CN1252231A (en) | Hemoglobin food series and its production process | |
| CN107279620A (en) | A kind of electrolyte beverage composition and preparation method thereof | |
| CN102948733A (en) | Production method and formula of special-eating life nutrition liquid | |
| CN107412261A (en) | With clear sugared oral liquid for repairing metabolic function and preparation method thereof | |
| CN100515429C (en) | Calcium and magnesium supplementing medicinal preparation | |
| CN101117316A (en) | Oral liquid for preventing and remitting diabetes | |
| CN110122866A (en) | A kind of the special medicine purposes food and preparation method of chronic kidney disease angiosteosis | |
| CN1225920A (en) | Method for preparing amino acid-magnesium chelate and use thereof | |
| US20100016438A1 (en) | Granulated crystal compilation composed of pure organic minerals used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal effects | |
| CN107595829B (en) | A kind of composition for preventing and treating renal osteodystrophy | |
| CN113749246B (en) | Preparation of eucommia ulmoides extract and application of eucommia ulmoides extract in formula food with full nutrition and special medical application | |
| CN1130999A (en) | VC calcium-enriching drink and production method thereof | |
| Yeboah et al. | Metabolic Pathology in Early Postnatal Ontogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |